The tumor-suppressor genes represented by the missense mutations in SMAD4, which encodes the transforming growth factor beta (TGFβ) signaling, are found in about 55% of pancreatic cancer patients, and are associated with a poor prognosis [16]. This evidence concerns the gene SMAD4 and neoplasm.